(TGTX) TG Therapeutics - Ratings and Ratios
Anti-CD20 Antibody, BTK Inhibitor, Bispecific Antibody, Relapsing Multiple Sclerosis, Lymphoma/Leukemia
TGTX EPS (Earnings per Share)
TGTX Revenue
Description: TGTX TG Therapeutics November 06, 2025
TG Therapeutics (NASDAQ:TGTX) is a commercial-stage biopharma focused on B-cell mediated diseases, primarily in the United States but with a growing international footprint. Its flagship product, BRIUMVI (ublituximab), is an anti-CD20 monoclonal antibody approved for adult relapsing multiple sclerosis (RMS) subtypes, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
The pipeline builds on the same anti-CD20 platform with Ublituximab IV for RMS, a covalent BTK inhibitor (TG-1701) that is orally administered, and a bispecific CD47/CD19 antibody (TG-1801) aimed at hematologic malignancies. The company also holds a suite of licensing and collaboration agreements with partners such as LFB Biotechnologies, Ildong Pharmaceutical, Jiangsu Hengrui, and Checkpoint Therapeutics to co-develop and commercialize its assets.
From the most recent 10-K (FY 2023), TG Therapeutics reported net product revenue of approximately $140 million, driven largely by BRIUMVI sales, and a cash runway of roughly 12 months at current burn rates. The firm’s R&D spend was $115 million, reflecting heavy investment in late-stage trials for TG-1701 and TG-1801. As of the latest market data, the company’s market capitalization sits near $2.5 billion, with a forward-looking price-to-sales multiple of about 18×, well above the biotech sector average of 12×.
Key economic drivers include the expanding global MS market-projected to exceed $15 billion by 2028-and the broader BTK inhibitor space, which is expected to grow at a CAGR of ~10% as clinicians seek oral alternatives to intravenous therapies. However, uncertainties remain around the ability of TG-1701 to differentiate itself from established BTK competitors (e.g., ibrutinib, acalabrutinib) and the regulatory timeline for TG-1801. For a deeper quantitative assessment of TG Therapeutics’ valuation and risk profile, a review of the detailed analytics on ValueRay can provide useful context.
TGTX Stock Overview
| Market Cap in USD | 5,518m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1995-12-14 |
TGTX Stock Ratings
| Growth Rating | 42.8% |
| Fundamental | 66.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 6.64% |
| Analyst Rating | 4.43 of 5 |
TGTX Dividends
Currently no dividends paidTGTX Growth Ratios
| Growth Correlation 3m | 72.1% |
| Growth Correlation 12m | 17.6% |
| Growth Correlation 5y | 4.7% |
| CAGR 5y | 58.69% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.73 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.82 |
| Sharpe Ratio 12m | 0.47 |
| Alpha | 3.09 |
| Beta | 1.967 |
| Volatility | 68.19% |
| Current Volume | 1496.8k |
| Average Volume 20d | 1613.6k |
| Stop Loss | 31.5 (-5.3%) |
| Signal | -0.29 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (60.5m TTM) > 0 and > 6% of Revenue (6% = 27.2m TTM) |
| FCFTA -0.08 (>2.0%) and ΔFCFTA -25.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 108.4% (prev 80.90%; Δ 27.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -59.1m <= Net Income 60.5m (YES >=105%, WARN >=100%) |
| Net Debt (124.6m) to EBITDA (97.1m) ratio: 1.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (162.6m) change vs 12m ago 1.97% (target <= -2.0% for YES) |
| Gross Margin 86.96% (prev 92.71%; Δ -5.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 82.27% (prev 86.42%; Δ -4.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.09 (EBITDA TTM 97.1m / Interest Expense TTM 31.4m) >= 6 (WARN >= 3) |
Altman Z'' -4.85
| (A) 0.70 = (Total Current Assets 664.0m - Total Current Liabilities 171.9m) / Total Assets 702.6m |
| (B) -2.13 = Retained Earnings (Balance) -1.50b / Total Assets 702.6m |
| warn (B) unusual magnitude: -2.13 — check mapping/units |
| (C) 0.18 = EBIT TTM 96.8m / Avg Total Assets 551.9m |
| (D) -3.51 = Book Value of Equity -1.50b / Total Liabilities 426.2m |
| Total Rating: -4.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.67
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -1.07% = -0.54 |
| 3. FCF Margin -13.05% = -4.89 |
| 4. Debt/Equity 0.92 = 2.10 |
| 5. Debt/Ebitda 1.28 = 1.33 |
| 6. ROIC - WACC (= 8.47)% = 10.58 |
| 7. RoE 26.05% = 2.17 |
| 8. Rev. Trend 79.79% = 5.98 |
| 9. EPS Trend 38.68% = 1.93 |
What is the price of TGTX shares?
Over the past week, the price has changed by -2.23%, over one month by -9.52%, over three months by +20.07% and over the past year by +22.41%.
Is TG Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TGTX is around 29.58 USD . This means that TGTX is currently overvalued and has a potential downside of -11.06%.
Is TGTX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the TGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.6 | 31% |
| Analysts Target Price | 43.6 | 31% |
| ValueRay Target Price | 34.3 | 3% |
TGTX Fundamental Data Overview November 02, 2025
P/E Trailing = 91.5263
P/E Forward = 42.9185
P/S = 12.1532
P/B = 21.042
Beta = 1.967
Revenue TTM = 454.1m USD
EBIT TTM = 96.8m USD
EBITDA TTM = 97.1m USD
Long Term Debt = 245.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.90m USD (from shortTermDebt, last quarter)
Debt = 253.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 124.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.52b USD (5.52b + Debt 253.7m - CCE 251.9m)
Interest Coverage Ratio = 3.09 (Ebit TTM 96.8m / Interest Expense TTM 31.4m)
FCF Yield = -1.07% (FCF TTM -59.2m / Enterprise Value 5.52b)
FCF Margin = -13.05% (FCF TTM -59.2m / Revenue TTM 454.1m)
Net Margin = 13.31% (Net Income TTM 60.5m / Revenue TTM 454.1m)
Gross Margin = 86.96% ((Revenue TTM 454.1m - Cost of Revenue TTM 59.2m) / Revenue TTM)
Gross Margin QoQ = 86.58% (prev 87.14%)
Tobins Q-Ratio = 7.86 (Enterprise Value 5.52b / Total Assets 702.6m)
Interest Expense / Debt = 2.65% (Interest Expense 6.72m / Debt 253.7m)
Taxrate = 8.84% (2.73m / 30.9m)
NOPAT = 88.3m (EBIT 96.8m * (1 - 8.84%))
Current Ratio = 3.86 (Total Current Assets 664.0m / Total Current Liabilities 171.9m)
Debt / Equity = 0.92 (Debt 253.7m / totalStockholderEquity, last quarter 276.4m)
Debt / EBITDA = 1.28 (Net Debt 124.6m / EBITDA 97.1m)
Debt / FCF = -2.10 (negative FCF - burning cash) (Net Debt 124.6m / FCF TTM -59.2m)
Total Stockholder Equity = 232.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.60% (Net Income 60.5m / Total Assets 702.6m)
RoE = 26.05% (Net Income TTM 60.5m / Total Stockholder Equity 232.1m)
RoCE = 20.30% (EBIT 96.8m / Capital Employed (Equity 232.1m + L.T.Debt 245.0m))
RoIC = 21.25% (NOPAT 88.3m / Invested Capital 415.5m)
WACC = 12.78% (E(5.52b)/V(5.77b) * Re(13.26%) + D(253.7m)/V(5.77b) * Rd(2.65%) * (1-Tc(0.09)))
Discount Rate = 13.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.59%
Fair Price DCF = unknown (Cash Flow -59.2m)
EPS Correlation: 38.68 | EPS CAGR: 253.4% | SUE: -0.97 | # QB: 0
Revenue Correlation: 79.79 | Revenue CAGR: 1329 % | SUE: -0.13 | # QB: 0
Additional Sources for TGTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle